Promoter Increases Stake in Goldline Pharmaceutical
Goldline Pharmaceutical Ltd 路 Acquisition/ Disposal of Shares 路 01 Sept 2026, 6:41 pm
Promoter Increases Stake in Goldline Pharmaceutical Amol Laxmikant Mujumdar, Promoter and Managing Director, acquired 60,000 equity shares (0.62% of total capital) via an open market purchase on 31 Aug'26. This transaction increases his total shareholding from 2,749,988 shares (28.64%) to 2,809,988 shares (29.27%). The purchase signals strengthened promoter confidence. The company's total issued capital remains at 9,600,000 equity shares post-acquisition. This disclosure was made under SEBI (SAST) Regulations, 2011.
Original exchange filing (PDF)
More announcements from Goldline Pharmaceutical Ltd
- Submission of statement of deviation and variation of the half year ended 30th september 2026 路 15 Nov 2026
- Declaration of Un-audited Standalone Financial Results of the company for the half year ended September 30, 2026 路 15 Nov 2026
- Outcome of Board Meeting dated 14th November, 2026 pursuant to Reg 30 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 & Submission .... 路 15 Nov 2026
- Goldline Pharmaceutical Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026 ,inter alia, to consider and approve The Standalone Unaudited .... 路 14 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Amol Mujumdar 路 02 Sept 2026
- Scrutinizer Report 路 31 Aug 2026
- AGM Proceedings of the 22nd Annual General Meeting (AGM) of the Company pertaining to Financial Year 2025-26. 路 30 Aug 2026
